Key facts
- Tessera Therapeutics’s last known valuation is $650.0M (Dec 2024).
- It has raised $630.0M; the latest was Later Stage VC in Dec 2025.
- Notable investors include SoftBank Investment Advisers, University of California, Gates Foundation, EDBI, Qatar Investment Authority — 29 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 29 names
- ·Watchlist + deal alerts for Tessera Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Tessera Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tessera Therapeutics
Developer of a gene writing technology designed to make permanent small and large alterations to the human genome. The company's technology helps scientists and clinicians with the ability to write small and large therapeutic messages into the genome to treat diseases at their source, enabling healthcare providers to cure their patients and improve their lives.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2018
- Employees
- 292
- Website
- tesseratherapeutics.com/
- Ownership
- Privately Held (backing)
Tessera Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tessera Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tessera Therapeutics in its N-PORT filings yet. We sweep new filings monthly.